

Opto Circuits' subsidiary Eurocor gets registration for "DIOR®" in India

Bangalore, India | Bonn, Germany; 24th September 2008

Opto Circuits (India) Limited's wholly-owned subsidiary, Eurocor GmbH, has received registration for its drug-eluting balloon, DIOR® in India. The commercial release of DIOR® will commence after fulfilling the guidelines provided by Drug Control General of India (DCGI).

Coronary Angioplasty (PTCA) is a widely used method of treating patients with blocked arteries. Until recently the most recurring problem for the long-term durability of angioplasty is restenosis. Drug-eluting stents (DES) have markedly minimized this situation of restenosis (Re-closure of the culprit artery) but has not solved it entirely.

Euocor's novel product-"DIOR®" provides a solution to this problem. "DIOR®" is a drug-eluting balloon which can be used safely in patients with In-Stent restenosis, bifurcation lesions and lesions in small vessels (where putting a metal stent may not always be the treatment of choice).

"DIOR®" is a balloon catheter which is able to elute paclitaxel locally in the culprit lesion and clear the blockage (In cases of In-Stent restenosis) and also prevent it from re-occurring. The product is growing at a jet speed in the European countries and is CE mark approved.

The new concept of a drug-eluting balloon is going to bring about a revolution in the treatment of In-Stent restenosis case, where a patient comes back with stenosis (occlusion) inside the stented artery. Small vessel treatment: where putting a metal stent is not an option.

This new form of treatment is the future in the field of intervention and will gradually spread its wings into other areas as well.